URGN CMO sells 10,000 shares at $25 under 10b5-1 plan

UroGen Pharma Ltd. (URGN) reported an insider stock sale by its Chief Medical Officer.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) reported an insider stock sale by its Chief Medical Officer. On 11/19/2025, the officer sold 10,000 ordinary shares in an open market transaction coded as a sale. The weighted average sale price was $25.00, with individual trades occurring between $25.00 and $25.02 per share.

The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan that was adopted on 08/15/2025. After this sale, the officer directly beneficially owned 139,025 ordinary shares of UroGen Pharma.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Schoenberg Mark

Role Chief Medical Officer

Sold 10,000 shs ($250K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	10,000	$25.00	$250K

Holdings After Transaction: Ordinary Shares — 139,025 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UroGen Pharma (URGN) disclose in this Form 4?

The filing reports that UroGen Pharma's Chief Medical Officer sold 10,000 ordinary shares of URGN on 11/19/2025 in an open market sale.

At what price were the URGN shares sold in this Form 4 transaction?

The shares were sold at a weighted average price of $25.00 per share, with individual sale prices ranging from $25.00 to $25.02.

How many UroGen Pharma (URGN) shares does the insider own after the reported sale?

Following the reported transaction, the insider beneficially owned 139,025 ordinary shares of UroGen Pharma directly.

Was the URGN insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale was made pursuant to a Rule 10b5-1(c) trading plan that was duly adopted on 08/15/2025.

What does the weighted average price disclosure mean in the URGN Form 4?

The filing notes that the reported $25.00 price is a weighted average, with multiple trades between $25.00 and $25.02, and the insider will provide detailed breakdowns upon request.

Is this URGN Form 4 filed by one reporting person or a group?

The filing indicates that it is a Form filed by one reporting person, not a joint or group filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 01:42 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoenberg Mark

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/19/2025		S(1)		10,000	D	$25(2)	139,025	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	/s/ Jason D. Smith, Attorney-in-Fact	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.